Endocrine disruptors and prostate cancer

被引:0
作者
Sanchez de Bodojoz, Eduardo [1 ]
Maria Lage-Sanchez, Jose [1 ]
Sanchez-Gallegos, Pilar [1 ]
机构
[1] Univ Malaga, Fac Med, Dept Cirugia, Unidad Docente Urol, Malaga, Spain
来源
ARCHIVOS ESPANOLES DE UROLOGIA | 2017年 / 70卷 / 03期
关键词
Endocrine disruptors; Prostate cancer; Cholesterol; Toxic; Obesity; Hormonodependent cancer; CELLS; RISK;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES: Although prostate cancer is probably the most frequent cancer in men, little is known about its etiology. Clear evidence exists about variations in the incidence of prostate cancer between populations living in different countries. These variations could be explained by differences in lifestyle and a possible association with a set of substances that are able to intervene in the origin of the disease. METHODS: The reason that lifestyle may be the cause of prostate cancer is related to endocrine disruptors. These are a group of chemical substances that can mimic or alter hormone signaling. These disruptors are able to exert their effect at very low doses and act insidiously over the years, even being able to pass their effect on from one generation to the next. Cholesterol is an essential precursor in the synthesis of androgens, estrogens and other substances that are active in prostate cancer. Cholesterol is a central metabolite in lipid metabolism, the inflammatory response and other elements involved in the formation and progression of cancer. High cholesterol concentrations can give rise to the accumulation of androgens in tumor cells. Additionally, endocrine disruptors have been identified as being responsible for processes related with fertility, genital malformations and various hormone dependent cancers. Disruptors already identified include diethylstilbestrol, dichlorodiphenyltrichloroethane (DDT), polychlorinated biphenyls and dioxins. RESULTS: Though no clear direct association has yet been found in humans between most endocrine disruptors and prostate cancer, evidence suggests that an inadequate diet and contact with certain toxic agents predisposes to the disease. These disruptors are known to be especially relevant at particular times, such as during pregnancy, neonatal stages and puberty. CONCLUSIONS: The problem with these toxic agents is that their peculiarities and way of acting over time make their study difficult. Nonetheless, research must be encouraged given their importance.
引用
收藏
页码:331 / 335
页数:5
相关论文
共 13 条
[1]  
Alfaqih MA, 2016, NAT REV UROL, DOI [10.1038/nrurol.2016.199, DOI 10.1038/NRUROL.2016.199]
[2]  
Arvelo F, 2016, INVEST CLIN, V57, P77
[3]   Electromagnetic fields, polychlorinated biphenyls, and prostate cancer mortality in electric utility workers [J].
Charles, LE ;
Loomis, D ;
Shy, CM ;
Newman, B ;
Millikan, R ;
Nylander-French, LA ;
Couper, D .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2003, 157 (08) :683-691
[4]  
Chevalier L., 2014, LIVRE ANTITOXIQUE, V08009, P102
[5]  
Davenport L., 2016, MEDSCAPE UROLOGY ADI
[6]   DIETHYLSTILBESTROL REVISITED - A REVIEW OF THE LONG-TERM HEALTH-EFFECTS [J].
GIUSTI, RM ;
IWAMOTO, K ;
HATCH, EE .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (10) :778-788
[7]   Actions of estrogens and endocrine disrupting chemicals on human prostate stem/progenitor cells and prostate cancer risk [J].
Hu, Wen-Yang ;
Shi, Guang-Bin ;
Hu, Dan-Ping ;
Nelles, Jason L. ;
Prins, Gail S. .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2012, 354 (1-2) :63-73
[8]   Potent inhibition of estrogen sulfotransferase by hydroxylated PCB metabolites: A novel pathway explaining the estrogenic activity of PCBs [J].
Kester, MHA ;
Bulduk, S ;
Tibboel, D ;
Meinl, W ;
Glatt, H ;
Falany, CN ;
Coughtrie, MWH ;
Bergman, A ;
Safe, SH ;
Kuiper, GGJM ;
Schuur, AG ;
Brouwer, A ;
Visser, TJ .
ENDOCRINOLOGY, 2000, 141 (05) :1897-1900
[9]   Effects of various pesticides on human 5α-reductase activity in prostate and LNCaP cells [J].
Lo, Susan ;
King, Isabella ;
Allera, Axel ;
Klingmueller, Dietrich .
TOXICOLOGY IN VITRO, 2007, 21 (03) :502-508
[10]   Cholesterol and prostate cancer [J].
Pelton, Kristine ;
Freeman, Michael R. ;
Solomon, Keith R. .
CURRENT OPINION IN PHARMACOLOGY, 2012, 12 (06) :751-759